Patient | MSKCC risk group | ECOG performance status at diagnosis of BM | Extracerebral metastatic site | TX prior first TA | Time from primary metastasis to BM (months) | BM-TX | CNS recurrence during/after TA | First TA | Best Response | PFS | Following TX lines | OS | Progressing metastatic site leading to death |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | fav | 0 | Lung | Cytokines | 0 | surg | no | SU | CR | 24.2 | Ongoing | 24.2 | non progressing and alive |
2 | interm | 0 | Lung | Cytokines, Capecitabin | 45 | surg | no | Beva | SD | 8.7 | SU Soraf Tems Tems+Beva | 46.9 | non progressing and alive |
3 | interm | 1 | lung, LN | no | 0 | surg, WBRT | no | SU | SD | 8.5 | ongoing | 8.5 | non progressing and alive |
4 | interm | 1 | lung, other | Cytokines | 72 | SR | no | Beva | SD | 21.6 | SU, Tems | 36.9 | lung, liver |
5 | fav | 0 | liver, bone, other | Cytokines, Navelbine | 27 | WBRT, SR | yes (progression in lesion size) | Soraf | PD | 2.6 | SU | 13.42 | lung. |
6 | interm | 1 | other | no | 0 | SR, WBRT | yes (progression in lesion size) | SU | PD | 3.4 | Tems, Beva +Interferon | 10.16 | Liver |
7 | interm | 0 | Ln | no | 0 | WBRT | no | SU | PR | 3.26 | Soraf | 18.82 | non progressing and alive |
8 | interm | 1 | lung | no | 0 | Surg, SR | no | SU | SD | 12.1 | SU | 40.6 | non progressing and alive |
9 | interm | 1 | lung, liver, other | no | 0 | SR | no | Tems | SD | 6.3 | no | 6.3 | liver, lung |
10 | interm | 0 | lung, ln | no | 8 | WBRT | no | Soraf | PR | 10.9 | no | 10.9 | Lung |
11 | interm | 0 | lung, other | Cytokines, Navelbine | 14 | Surg,WBRT | yes (relapse of resected lesion and new lesions) | SU | SD | 3.8 | no | 3.8 | cranial vertebral fractures |
12 | poor | 2 | bone | no | 0 | WBRT | No | SU | SD | 6.7 | no | 6.7 | Lung |